| 20th Sep 2022 9:34 am |
RNS |
New research presented on photodisinfection |
| 7th Sep 2022 12:30 pm |
RNS |
Ondine’s photodisinfection kills ESKAPE pathogens |
| 6th Sep 2022 7:00 am |
RNS |
Ondine reports successful US Phase 2 trial data |
| 31st Aug 2022 10:49 am |
RNS |
Nature reports Ondine therapy suppresses COVID-19 |
| 16th Aug 2022 7:00 am |
RNS |
Ondine appoints RBC and Singer as joint brokers |
| 8th Aug 2022 10:02 am |
RNS |
Ondine completes US Phase II trial recruitment |
| 26th Jul 2022 7:00 am |
RNS |
Completion of Nominated Adviser due diligence |
| 22nd Jul 2022 7:00 am |
RNS |
Issue of Equity |
| 19th Jul 2022 7:00 am |
RNS |
Ondine completes successful SARS-CoV-2 trial |
| 8th Jun 2022 7:00 am |
RNS |
Result of AGM |
| 7th Jun 2022 7:00 am |
RNS |
Posting of annual report |
| 19th May 2022 7:00 am |
RNS |
Full Year Results to 31 December 2021 |
| 17th May 2022 7:00 am |
RNS |
Notice of AGM |
| 10th May 2022 10:30 am |
RNS |
WHO calls for better infection prevention |
| 27th Apr 2022 4:30 pm |
RNS |
Appointment of Nominated Adviser |
| 5th Apr 2022 7:00 am |
RNS |
Photodisinfection effective against SARS-CoV-2 |
| 21st Feb 2022 7:00 am |
RNS |
Grant of Options and PDMR Dealing |
| 7th Feb 2022 7:00 am |
RNS |
Ondine treats first patients in Phase 2 FDA trial |
| 20th Dec 2021 7:00 am |
RNS |
Ondine and University of Navarra initiate clinical |
| 15th Dec 2021 7:00 am |
RNS |
Ondine Biomedical appoints Professor Trevor Jones |
| 7th Dec 2021 7:00 am |
RNS |
Ondine Biomedical appoints new Board of Directors |
| 6th Dec 2021 7:00 am |
RNS |
Ondine Biomedical announces AIM market listing |
